- The disease
- Diabetic foot ulcers (DFUs) are open sores or wounds that occur in people with diabetes, typically on the bottom of the foot. They are classified as chronic or non-healing when they fail to progress through the normal stages of wound repair. DFUs are associated with significant morbidity, risk of infection, and lower-limb amputation. They represent a substantial and growing clinical burden globally as rates of diabetes increase.
- What the asset is trying to do
- Symphony is a wound care biologic developed by Aroa Biosurgery. It is derived from Aroa's ovine (sheep) forestomach extracellular matrix (ECM) platform, which provides a scaffold intended to support tissue regeneration in complex wounds. The ECM material retains structural proteins found in native tissue and is designed to interact with the wound environment to support healing. No detailed mechanism-of-action text was provided in the input data; further product-specific detail is available in Aroa's published materials.
- What the trial is measuring, and why it matters
- The lead trial (NCT06035536) evaluated Symphony plus off-loading and a calcium alginate wound dressing (Fibracol) versus standard of care in patients with non-healing DFUs (per ClinicalTrials.gov NCT06035536). A second completed trial (NCT06035523) evaluated wound closure outcomes when Symphony was used alongside Aroa's Endoform products (per ClinicalTrials.gov NCT06035523). Wound closure is a standard primary endpoint in DFU studies because full closure is associated with reduced infection risk and reduced amputation rates. Aroa announced completion of the randomised controlled trial on 29 March 2026 (per ASX announcement, 29 March 2026).
- Efficacy benchmarks in this setting
- In the DFU wound care setting, approved and widely studied comparators have set the following benchmarks. Becaplermin gel (Regranex), an approved platelet-derived growth factor product, achieved complete wound closure in approximately 50% of patients versus approximately 35% for placebo at 20 weeks in its pivotal trial (Steed et al, Journal of Vascular Surgery, 1995, as cited in the Regranex US prescribing information). Apligraf (a bilayer cellular construct) achieved complete closure in 56% of DFU patients versus 38% for compression alone at 12 weeks in a pivotal study (Veves et al, Diabetes Care 2001). Figures from early or post-market studies of Symphony are not statistically comparable to these pivotal trial results, as trial designs, patient populations, and follow-up periods differ.
- Commercial context
- Symphony is a commercially approved product sold by Aroa Biosurgery (ASX: ARX), a New Zealand-based regenerative medicine company. The DFU advanced wound care market includes multiple approved products, including bioengineered skin substitutes, growth factor therapies, and ECM-based products, none of which has achieved dominant market share. Aroa's US commercial operations are conducted through its subsidiary and the company has disclosed that Symphony is part of its portfolio of ECM-based wound care products. Symphony's commercial status and its role within Aroa's portfolio are described in the FY26 Full Year Results released 25 May 2026 (per ASX announcement); specific revenue figures attributed to Symphony individually are .